Here is a list of the top 15 world’s largest pharmaceutical companies in the world based SOLELY on 2023 pharmaceutical drug and vaccine sales revenue.
Note:
- Revenues outside of the pharmaceutical drug and vaccine sales were excluded. E.g. Roche’s diagnostics, J&J’s medtech, MSD’s animal health, Bayer’s crop science and consumer health sales, etc.
- In addition, we only consider PLCs, not state-owned enterprises such as Sinopharm.
- Data was taken from company annual reports.
- Revenue in (USD Billions) for 2023 with percentage change from 2022.
1. Pfizer (US) – $58.5 billion -41%
2. Johnson & Johnson (US) – $54.80 billion +4%
3. AbbVie (US) – $54.32 billion -6%
4. Merck & Co. (US) – $53.58 billion +3%
5. Roche (Switzerland) – $48.7 billion -2%
6. AstraZeneca (Sweeden/UK) – $45.8 billion +3.3%
8. Novartis (Switzerland) – $45.44 billion -8%
7. Bristol-Myers Squibb (US) – $45.06 billion -2%
9. Sanofi S.A. (France) – $40.56 billion +0.3%
10. GlaxoSmithKline (UK) – $37.76 billion +3.4%
11. Eli Lilly (US) – $34.12 billion +20%
12. Novo Nordisk (Denmark) – $33.30 billion +31.5%
13. Takeda (Japan) – $30.30 billion +3.5
14. Amgen Inc (US) – $28.20 billion +7%
15. Gilead Sciences (US) – $27.12 billion -0.2%
Highlights:
- Pfizer retains the No.1 position. However, sales dropped from $100.3 billion in 2022 to $58.5 billion in 2023 due to a slowdown in the sales of its COVID-19 vaccine.
- Novo Nordisk’s revenues increased from $25.40 billion in 2022 to $33.30 billion in 2023 mostly due to demand for its diabetes and obesity products Ozempic and Wegovy.
- Eli Lilly saw a 20% jump in revenue from $28.54 billion to $34.12 billion mostly due to demand for to demand for its diabetes and obesity products Mounjaro and Zepbound.
- While Novartis’s total revenue dropped from $50.54 billion to $45.44 billion due to the spin-off of its generics and biosimilar business Sandoz, its core operating revenue grew by 7.7%.
Read also:
